A review on the use of prebiotics in ulcerative colitis.

Autor: Kennedy JM; Department of Food and Nutritional Sciences, The University of Reading, Reading, RG6 6AP, UK; Department of Gastroenterology, Royal Berkshire NHS Foundation Trust, Reading, RG1 5AN, UK. Electronic address: j.kennedy@pgr.reading.ac.uk., De Silva A; Department of Gastroenterology, Royal Berkshire NHS Foundation Trust, Reading, RG1 5AN, UK., Walton GE; Department of Food and Nutritional Sciences, The University of Reading, Reading, RG6 6AP, UK., Gibson GR; Department of Food and Nutritional Sciences, The University of Reading, Reading, RG6 6AP, UK.
Jazyk: angličtina
Zdroj: Trends in microbiology [Trends Microbiol] 2024 May; Vol. 32 (5), pp. 507-515. Date of Electronic Publication: 2023 Dec 07.
DOI: 10.1016/j.tim.2023.11.007
Abstrakt: The gut microbiome in the inflammatory bowel disease, ulcerative colitis (UC), is different to that of healthy controls. Patients with UC have relative reductions in abundance of Firmicutes and Bifidobacterium in the colon, and an increase in sulfate-reducing bacteria. Prebiotics are dietary substrates which are selectively metabolised by the human colonic microbiota to confer health benefits to the host. This review explores our current understanding of the potential benefits of prebiotics on various clinical, biochemical, and microbiological endpoints in UC, including new perspectives gained from recent studies in the field. This review looks to the future and highlights the need for appropriately designed trials to explore this potentially exciting new avenue for the treatment of UC.
Competing Interests: Declaration of interests No interests are declared.
(Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: